CN101076340B - Gaba-类固醇拮抗剂及其治疗cns障碍的用途 - Google Patents

Gaba-类固醇拮抗剂及其治疗cns障碍的用途 Download PDF

Info

Publication number
CN101076340B
CN101076340B CN2005800394888A CN200580039488A CN101076340B CN 101076340 B CN101076340 B CN 101076340B CN 2005800394888 A CN2005800394888 A CN 2005800394888A CN 200580039488 A CN200580039488 A CN 200580039488A CN 101076340 B CN101076340 B CN 101076340B
Authority
CN
China
Prior art keywords
gaba
pregnane
steroids
hydroxy
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800394888A
Other languages
English (en)
Chinese (zh)
Other versions
CN101076340A (zh
Inventor
T·巴克斯特龙
P·隆德格伦
王明德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Publication of CN101076340A publication Critical patent/CN101076340A/zh
Application granted granted Critical
Publication of CN101076340B publication Critical patent/CN101076340B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2005800394888A 2004-11-18 2005-11-07 Gaba-类固醇拮抗剂及其治疗cns障碍的用途 Expired - Fee Related CN101076340B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62951104P 2004-11-18 2004-11-18
US60/629,511 2004-11-18
PCT/SE2005/001671 WO2006054938A1 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of cns disorders

Publications (2)

Publication Number Publication Date
CN101076340A CN101076340A (zh) 2007-11-21
CN101076340B true CN101076340B (zh) 2011-01-12

Family

ID=36407411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800394888A Expired - Fee Related CN101076340B (zh) 2004-11-18 2005-11-07 Gaba-类固醇拮抗剂及其治疗cns障碍的用途

Country Status (11)

Country Link
US (2) US8114860B2 (https=)
EP (1) EP1812009B1 (https=)
JP (1) JP4914368B2 (https=)
CN (1) CN101076340B (https=)
AU (1) AU2005307151B2 (https=)
BR (1) BRPI0518359A2 (https=)
CA (1) CA2585359C (https=)
DK (1) DK1812009T3 (https=)
ES (1) ES2423493T3 (https=)
MX (1) MX2007006032A (https=)
WO (1) WO2006054938A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054938A1 (en) 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
DK2097437T3 (en) * 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
HUE027298T2 (en) 2010-01-14 2016-10-28 Asarina Pharma Ab Pharmaceutical composition containing developed storage and dissolution properties containing 3-beta-hydroxy-5-alpha-pregnan-20-one
WO2023148234A1 (en) 2022-02-04 2023-08-10 Rousselot Bv Use of collagen hydrolysate in prevention and/or treatment of food craving

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059357A1 (en) * 2001-12-27 2003-07-24 Umecrine Ab Pregnane steroids for use in the treatment of cns disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614499A (en) * 1985-04-29 1986-09-30 Universite Laval Simulator for use as a neurosurgical aid in determining potential paths for the implantation of probes through the human body
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US20030125311A1 (en) * 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
WO2006054938A1 (en) 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059357A1 (en) * 2001-12-27 2003-07-24 Umecrine Ab Pregnane steroids for use in the treatment of cns disorders

Also Published As

Publication number Publication date
EP1812009A4 (en) 2010-08-11
JP4914368B2 (ja) 2012-04-11
AU2005307151A1 (en) 2006-05-26
BRPI0518359A2 (pt) 2008-11-18
MX2007006032A (es) 2007-10-17
US8114860B2 (en) 2012-02-14
JP2008525317A (ja) 2008-07-17
CN101076340A (zh) 2007-11-21
US20080070876A1 (en) 2008-03-20
US8372824B2 (en) 2013-02-12
CA2585359A1 (en) 2006-05-26
EP1812009A1 (en) 2007-08-01
WO2006054938A1 (en) 2006-05-26
CA2585359C (en) 2013-01-08
AU2005307151B2 (en) 2011-10-20
EP1812009B1 (en) 2013-05-15
ES2423493T3 (es) 2013-09-20
US20120142657A1 (en) 2012-06-07
DK1812009T3 (da) 2013-08-05

Similar Documents

Publication Publication Date Title
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
JP5913136B2 (ja) 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
JP2013523683A5 (https=)
JP2013518908A5 (https=)
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
Dooms‐Goossens et al. Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasone butyrate
Claman Glucocorticosteroids II: the clinical responses
WO2023163945A1 (en) Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
Deepalakshmi et al. A Comprehensive Review on Corticosteroids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110112

Termination date: 20201107

CF01 Termination of patent right due to non-payment of annual fee